ロード中...
Eribulin—A review of preclinical and clinical studies
Eribulin mesylate is a non-taxane, structurally simplified, completely synthetic, halichondrin B derivative with an end poisoning, microtubule inhibitory action. Preclinical studies have demonstrated activity in various cancer cell lines and synergistic action with gemcitabine, epirubicin, trastuzum...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2011
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3954568/ https://ncbi.nlm.nih.gov/pubmed/21493087 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.critrevonc.2011.03.002 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|